Verition Fund Management
AXSM icon

Verition Fund Management’s Axsome Therapeutics AXSM Stock Holding History

Verition Fund Management’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.22M Buy
+5,000
New +$1.08M 0.01% 1350

Other funds holding AXSM

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Verition Fund Management's AXSM Position: Q2 2026 in Review

Verition Fund Management opened a new position in Axsome Therapeutics (AXSM) in Q2 2026: 6,000 shares worth $1.47M. The stake represents 0.01% of the portfolio and ranks #1259 among its holdings. This is a return to the name: Verition Fund Management previously reported a position in AXSM as recently as Q4 2025.

Verition Fund Management first reported a position in AXSM in Q1 2020 and has held it in 8 quarters since. The position peaked at $3.38M in Q1 2025. 506 funds tracked by Wall St. Rank hold AXSM as of Q2 2026.

  • Verition Fund Management held 6,000 shares of Axsome Therapeutics worth $1.47M as of Q2 2026.
  • Axsome Therapeutics was a new Verition Fund Management position in Q2 2026.
  • Axsome Therapeutics made up 0.01% of Verition Fund Management's portfolio in Q2 2026, its #1259 holding.
  • Verition Fund Management first reported a position in Axsome Therapeutics in Q1 2020 and has held it in 8 quarters since.
  • Verition Fund Management's Axsome Therapeutics position peaked at $3.38M in Q1 2025.
  • 506 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q2 2026.

Based on Verition Fund Management's 13F filing for Q2 2026, filed 14 Aug 2026.